Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04605159
Registration number
NCT04605159
Ethics application status
Date submitted
22/10/2020
Date registered
27/10/2020
Date last updated
25/03/2025
Titles & IDs
Public title
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
Query!
Scientific title
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Query!
Secondary ID [1]
0
0
2020-001355-40
Query!
Secondary ID [2]
0
0
212171
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GRACE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - RSV MAT
Treatment: Drugs - Placebo
Experimental: RSV MAT Group - Mother - Maternal participants received a single dose of the RSV MAT vaccine administered at Day 1 in this study.
Placebo comparator: Placebo Group - Mother - Maternal participants received a single dose of placebo administered at Day 1 in this study.
No intervention: RSV MAT Group - Infant - This group consisted of infants born to mothers (from RSV MAT Group - Mother) who received a single dose of RSV MAT vaccine during pregnancy.
No intervention: Placebo Group - Infant - This group consisted of infants born to mothers (from Placebo Group - Mother) who received a single dose of placebo during pregnancy.
Treatment: Other: RSV MAT
One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
Treatment: Drugs: Placebo
One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated Lower Respiratory Tract Illnesses (LRTIs) of Any Severity and RSV-associated Severe LRTIs From Birth to Day 181 Post-birth
Query!
Assessment method [1]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND a blood oxygen saturation by pulse oximetry (SpO2) lower than (\<) 95%, OR respiratory rate increase AND a confirmed RSV infection. An RSV-associated severe LRTI met the case definition of RSV-LRTI AND was additionally characterized by a SpO2 \<93%, OR lower chest wall in-drawing, OR inability to feed, OR failure to respond/unconscious. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI.
Query!
Timepoint [1]
0
0
From birth to Day 181 post-birth
Query!
Primary outcome [2]
0
0
Number of Infant Participants With at Least One Serious Adverse Event (SAE) From Birth to Day 181 Post-birth
Query!
Assessment method [2]
0
0
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect or resulted in other situations that were considered serious per medical or scientific judgment. At least one SAE = occurrence of at least one SAE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [2]
0
0
From birth to Day 181 post-birth
Query!
Primary outcome [3]
0
0
Number of Infant Participants With at Least One Adverse Event (AE) Leading to Study Withdrawal From Birth to Day 181 Post-birth
Query!
Assessment method [3]
0
0
A participant was considered a 'withdrawal' from the study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this participant from the date of withdrawal/last contact. Participants who were withdrawn from the study because of AEs were clearly distinguished from participants who were withdrawn for other reasons. Investigators followed participants who were withdrawn from the study as a result of an AE until the event was resolved. At least one AE leading to study withdrawal = occurrence of at least one AE leading to study withdrawal regardless of intensity grade or relation to vaccination.
Query!
Timepoint [3]
0
0
From birth to Day 181 post-birth
Query!
Primary outcome [4]
0
0
Number of Infant Participants With at Least One Medically Attended AE (MAE) From Birth to Day 181 Post-birth
Query!
Assessment method [4]
0
0
An MAE is defined as an unsolicited AE, such as a symptom or illness, which required hospitalization, or emergency room visit, or visit to/by a health care provider. At least one MAE = occurrence of at least one MAE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [4]
0
0
From birth to Day 181 post-birth
Query!
Primary outcome [5]
0
0
Number of Infant Participants With at Least One SAE From Birth to Day 366 Post-birth
Query!
Assessment method [5]
0
0
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect or resulted in other situations that were considered serious per medical or scientific judgment. At least one SAE = occurrence of at least one SAE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [5]
0
0
From birth to Day 366 post-birth
Query!
Primary outcome [6]
0
0
Number of Infant Participants With at Least One AE Leading to Study Withdrawal From Birth to Day 366 Post-birth
Query!
Assessment method [6]
0
0
A participant was considered a 'withdrawal' from the study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this participant from the date of withdrawal/last contact. Participants who were withdrawn from the study because of AEs were clearly distinguished from participants who were withdrawn for other reasons. Investigators followed participants who were withdrawn from the study as a result of an AE until the event was resolved. At least one AE leading to study withdrawal = occurrence of at least one AE leading to study withdrawal regardless of intensity grade or relation to vaccination.
Query!
Timepoint [6]
0
0
From birth to Day 366 post-birth
Query!
Primary outcome [7]
0
0
Number of Infant Participants With at Least One MAE From Birth to Day 366 Post-birth
Query!
Assessment method [7]
0
0
An MAE is defined as an unsolicited AE, such as a symptom or illness, which required hospitalization, or emergency room visit, or visit to/by a health care provider. At least one MAE = occurrence of at least one MAE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [7]
0
0
From birth to Day 366 post-birth
Query!
Secondary outcome [1]
0
0
Number of Infant Participants With RSV-associated Hospitalizations From Birth to Day 181 Post-birth
Query!
Assessment method [1]
0
0
RSV-associated hospitalization is defined as a confirmed RSV infection and hospitalized for acute medical condition. Hospitalization is defined as admission for observation or treatment based on the judgment of a health care provider.
Query!
Timepoint [1]
0
0
From birth to Day 181 post-birth
Query!
Secondary outcome [2]
0
0
Number of Infant Participants With All-cause LRTIs From Birth to Day 181 Post-birth
Query!
Assessment method [2]
0
0
All-cause LRTI was characterized by history of cough OR difficulty in breathing, AND SpO2 \< 95%, OR respiratory rate increase.
Query!
Timepoint [2]
0
0
From birth to Day 181 post-birth
Query!
Secondary outcome [3]
0
0
Number of Infant Participants With All-cause LRTIs With Hospitalization From Birth to Day 181 Post-birth
Query!
Assessment method [3]
0
0
All-cause LRTI was characterized by history of cough OR difficulty in breathing, AND SpO2 \< 95%, OR respiratory rate increase. Hospitalization is defined as admission for observation or treatment based on the judgment of a health care provider.
Query!
Timepoint [3]
0
0
From birth to Day 181 post-birth
Query!
Secondary outcome [4]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated Severe LRTIs From Birth to Day 366 Post-birth
Query!
Assessment method [4]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND an SpO2 \<95%, OR respiratory rate increase AND a confirmed RSV infection. An RSV-associated severe LRTI met the case definition of RSV-LRTI AND was additionally characterized by an SpO2 \<93%, OR lower chest wall in-drawing, OR inability to feed, OR failure to respond/unconscious. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI.
Query!
Timepoint [4]
0
0
From birth to Day 366 post-birth
Query!
Secondary outcome [5]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated LRTIs of Any Severity From Birth to Day 366 Post-birth
Query!
Assessment method [5]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND an SpO2 \<95%, OR respiratory rate increase AND a confirmed RSV infection. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI.
Query!
Timepoint [5]
0
0
From birth to Day 366 post-birth
Query!
Secondary outcome [6]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated Severe LRTIs for RSV Subtype A and RSV Subtype B Separately From Birth to Day 181 Post-birth
Query!
Assessment method [6]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND an SpO2 \<95%, OR respiratory rate increase AND a confirmed RSV infection. An RSV-associated severe LRTI met the case definition of RSV-LRTI AND was additionally characterized by an SpO2 \<93%, OR lower chest wall in-drawing, OR inability to feed, OR failure to respond/unconscious. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI. The RSV subtypes assessed for this analysis were RSV subtype A and RSV subtype B.
Query!
Timepoint [6]
0
0
From birth to Day 181 post-birth
Query!
Secondary outcome [7]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated LRTIs of Any Severity for RSV Subtype A and RSV Subtype B Separately From Birth to Day 181 Post-birth
Query!
Assessment method [7]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND an SpO2 \<95%, OR respiratory rate increase AND a confirmed RSV infection. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI. The RSV subtypes assessed for this analysis were RSV subtype A and RSV subtype B.
Query!
Timepoint [7]
0
0
From birth to Day 181 post-birth
Query!
Secondary outcome [8]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated Severe LRTIs From Birth to Day 121 Post-birth
Query!
Assessment method [8]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND an SpO2 \<95%, OR respiratory rate increase AND a confirmed RSV infection. An RSV-associated severe LRTI met the case definition of RSV-LRTI AND was additionally characterized by an SpO2 \<93%, OR lower chest wall in-drawing, OR inability to feed, OR failure to respond/unconscious. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI.
Query!
Timepoint [8]
0
0
From birth to Day 121 post-birth
Query!
Secondary outcome [9]
0
0
Number of Infant Participants With Medically Assessed, RSV-associated LRTIs of Any Severity From Birth to Day 121 Post-birth
Query!
Assessment method [9]
0
0
An RSV-associated LRTI of any severity was characterized by a history of cough OR difficulty in breathing, AND an SpO2 \<95%, OR respiratory rate increase AND a confirmed RSV infection. Medically assessed = the infant was evaluated by a healthcare professional for the LRTI.
Query!
Timepoint [9]
0
0
From birth to Day 121 post-birth
Query!
Secondary outcome [10]
0
0
Number of Infant Participants With All-cause Pneumonia From Birth to Day 181 Post-birth
Query!
Assessment method [10]
0
0
The number of infant participants with all-cause pneumonia is presented in this outcome measure.
Query!
Timepoint [10]
0
0
From birth to Day 181 post-birth
Query!
Secondary outcome [11]
0
0
Number of Infant Participants With RSV-associated Hospitalizations From Birth to Day 366 Post-birth
Query!
Assessment method [11]
0
0
RSV-associated hospitalization is defined as a confirmed RSV infection and hospitalized for acute medical condition. Hospitalization is defined as admission for observation or treatment based on the judgment of a health care provider.
Query!
Timepoint [11]
0
0
From birth to Day 366 post-birth
Query!
Secondary outcome [12]
0
0
Number of Maternal Participants With RSV-associated Medically Attended RTIs (RSV-MA-RTIs) From Study Intervention Administration (Day 1) to Day 181 Post-delivery
Query!
Assessment method [12]
0
0
RSV-associated MA-RTI is defined as a medically attended visit for RTI symptoms and confirmed RSV infection.
Query!
Timepoint [12]
0
0
From study intervention administration (Day 1) to Day 181 post-delivery
Query!
Secondary outcome [13]
0
0
RSV-A Neutralizing Antibody Titers for Maternal Participants at Day 1, at Day 31 and at Delivery
Query!
Assessment method [13]
0
0
RSV-A neutralizing titers were determined by neutralization assay and expressed as geometric mean titers (GMTs).
Query!
Timepoint [13]
0
0
At Day 1 (before study intervention administration), at Day 31 and at delivery
Query!
Secondary outcome [14]
0
0
RSV-A Neutralizing Antibody Titers for Infant Participants at Delivery or Within 72 Hours After Birth
Query!
Assessment method [14]
0
0
RSV-A neutralizing titers were determined by neutralization assay and expressed as GMTs. The titers were measured on the cord blood sample collected at delivery, or on a blood sample collected from the infant within 72 hours after birth (if no cord blood sample could be obtained).
Query!
Timepoint [14]
0
0
At delivery or within 72 hours after birth
Query!
Secondary outcome [15]
0
0
RSV-A Neutralizing Antibody Titers for Infant Participants at Day 43 Post-birth
Query!
Assessment method [15]
0
0
RSV-A neutralizing titers were determined by neutralization assay and expressed as GMTs.
Query!
Timepoint [15]
0
0
At Day 43 post-birth
Query!
Secondary outcome [16]
0
0
RSV-A Neutralizing Antibody Titers for Infant Participants at Day 121 Post-birth
Query!
Assessment method [16]
0
0
RSV-A neutralizing titers were determined by neutralization assay and expressed as GMTs.
Query!
Timepoint [16]
0
0
At Day 121 post-birth
Query!
Secondary outcome [17]
0
0
RSV-A Neutralizing Antibody Titers for Infant Participants at Day 181 Post-birth
Query!
Assessment method [17]
0
0
RSV-A neutralizing titers were determined by neutralization assay and expressed as GMTs.
Query!
Timepoint [17]
0
0
At Day 181 post-birth
Query!
Secondary outcome [18]
0
0
RSV MAT Immunoglobulin G (IgG)-Specific Antibody Concentrations for Maternal Participants at Delivery
Query!
Assessment method [18]
0
0
RSV MAT IgG-specific antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (ELU/mL).
Query!
Timepoint [18]
0
0
At delivery
Query!
Secondary outcome [19]
0
0
RSV MAT IgG-specific Antibody Concentrations for Infant Participants at Delivery or Within 72 Hours After Birth
Query!
Assessment method [19]
0
0
RSV MAT IgG-specific antibody concentrations were determined by ELISA and expressed as GMCs in ELU/mL. The antibody concentrations were measured on the cord blood sample collected at delivery, or on a blood sample collected from the infant within 72 hours after birth (only if no cord blood sample could be obtained at delivery).
Query!
Timepoint [19]
0
0
At delivery or within 72 hours after birth (only if no cord blood sample could be obtained at delivery)
Query!
Secondary outcome [20]
0
0
Geometric Mean Ratio (GMR) Between Cord Blood and Maternal RSV MAT Immunoglobulin G (IgG)-Specific Antibody Concentrations
Query!
Assessment method [20]
0
0
The placental transfer ratio of RSV-MAT IgG-specific antibody concentration was determined from cord blood over that of the blood sample from mother at delivery. If no cord blood could be obtained, an infant blood sample was collected 72 hours after birth.
Query!
Timepoint [20]
0
0
At delivery (for maternal participants) or within 72 hours after birth (for infant participants, only if no cord blood could be obtained)
Query!
Secondary outcome [21]
0
0
Number of Maternal Participants With Any Solicited Administration Site Events From Day 1 to Day 7 Included
Query!
Assessment method [21]
0
0
Assessed solicited administration site events included erythema, pain and swelling at the injection site. Any pain = occurrence of the symptom regardless of intensity grade. Any erythema and swelling = symptom reported with a surface diameter greater than or equal to 20 millimeters.
Query!
Timepoint [21]
0
0
From Day 1 to Day 7 included
Query!
Secondary outcome [22]
0
0
Number of Maternal Participants With Any Solicited Systemic Events From Day 1 to Day 7 Included
Query!
Assessment method [22]
0
0
Assessed solicited systemic events included abdominal pain, diarrhea, fatigue, headache, nausea, fever \[temperature equal to or above (\>=) 38 degrees Celsius (°C)/100.4 degrees Fahrenheit (°F), regardless of the location of measurement\] and vomiting. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.
Query!
Timepoint [22]
0
0
From Day 1 to Day 7 included
Query!
Secondary outcome [23]
0
0
Number of Maternal Participants With Any Unsolicited AEs From Day 1 to Day 30 Included
Query!
Assessment method [23]
0
0
An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Any = occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [23]
0
0
From Day 1 to Day 30 included
Query!
Secondary outcome [24]
0
0
Number of Maternal Participants With at Least One SAE From Day 1 to Day 181 Post-delivery
Query!
Assessment method [24]
0
0
An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant or resulted in abnormal pregnancy outcomes or in other situations that were considered serious per medical or scientific judgment. At least one SAE = occurrence of at least one SAE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [24]
0
0
From Day 1 to Day 181 post-delivery
Query!
Secondary outcome [25]
0
0
Number of Maternal Participants With at Least One AE Leading to Study Withdrawal From Day 1 to Day 181 Post-delivery
Query!
Assessment method [25]
0
0
A participant was considered a 'withdrawal' from the study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this participant from the date of withdrawal/last contact. Participants who were withdrawn from the study because of AEs were clearly distinguished from participants who were withdrawn for other reasons. Investigators followed participants who were withdrawn from the study as a result of an AE until the event was resolved. At least one AE leading to study withdrawal = occurrence of at least one AE leading to study withdrawal regardless of intensity grade or relation to vaccination.
Query!
Timepoint [25]
0
0
From Day 1 to Day 181 post-delivery
Query!
Secondary outcome [26]
0
0
Number of Maternal Participants With at Least One All-cause MA-RTI From Day 1 to Day 181 Post-delivery
Query!
Assessment method [26]
0
0
All-cause MA-RTI occurred when the maternal participant visited a healthcare professional (e.g., a General Practitioner) for any respiratory symptom, including (but not limited to) cough, sore throat, sputum production and difficulty breathing. At least one all-cause MA-RTI = occurrence of at least one all-cause MA-RTI regardless of intensity grade or relation to vaccination.
Query!
Timepoint [26]
0
0
From Day 1 to Day 181 post-delivery
Query!
Secondary outcome [27]
0
0
Number of Maternal Participants With at Least One MAE From Day 1 to Day 42 Post-delivery
Query!
Assessment method [27]
0
0
An MAE is defined as an unsolicited AE, such as a symptom or illness, which required hospitalization, or emergency room visit, or visit to/by a health care provider. At least one MAE = occurrence of at least one MAE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [27]
0
0
From Day 1 to Day 42 post-delivery, an average of 2 months
Query!
Secondary outcome [28]
0
0
Number of Maternal Participants With Pregnancy Outcomes From Day 1 to Day 42 Post-delivery
Query!
Assessment method [28]
0
0
Assessed pregnancy outcomes included live birth with no congenital anomalies, live birth with minor congenital anomaly(ies), live birth with at least 1 major congenital anomaly, fetal death/still birth with no congenital anomalies, fetal death/still birth with at least 1 major congenital anomaly and unknown outcome (includes participants withdrawn before/at delivery with no available data of pregnancy outcomes).
Query!
Timepoint [28]
0
0
From Day 1 to Day 42 post-delivery, an average of 2 months
Query!
Secondary outcome [29]
0
0
Number of Maternal Participants With Pregnancy-related Adverse Events of Special Interest (AESIs) From Day 1 to Day 42 Post-delivery
Query!
Assessment method [29]
0
0
Pregnancy-related AESIs included chorioamnionitis, fetal growth restriction, gestational diabetes mellitus, gestational hypertension, pre-eclampsia, pre-eclampsia with severe features including eclampsia, maternal death, premature preterm rupture of membranes, preterm labor, provider-initiated preterm birth.
Query!
Timepoint [29]
0
0
From Day 1 to Day 42 post-delivery, an average of 2 months
Query!
Secondary outcome [30]
0
0
Number of Infant Participants With Neonatal AESIs From Birth to Day 42 Post-birth
Query!
Assessment method [30]
0
0
Neonatal/infant AESIs included congenital anomalies with functional defects, congenital anomalies with internal structural defects, congenital anomalies with major external structural defects, extremely low birth weight (\<1000 grams), low birth weight (\<2500 grams), very low birth weight (\<1500 grams), neonatal death in a preterm live birth (gestational age \>=28 and \<37 weeks), neonatal death in a term live birth (\>=37 weeks of gestational age), neonatal death in an extremely pre-term birth (gestational age \>=22 and \<28 weeks), preterm birth (\<37 weeks of gestational age), small for gestational age.
Query!
Timepoint [30]
0
0
From birth to Day 42 post-birth, an average of 2 months
Query!
Eligibility
Key inclusion criteria
Maternal participants
* Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Participants who give written or witnessed/thumb printed informed consent after the study has been explained, and before any study specific procedures are performed, as per local regulations regulatory requirements.
* Age 18 to 49 years, inclusive, at the time of study intervention.
* Pre-pregnancy BMI 17.0 to 39.9 kg/m2, inclusive.
* In good general maternal health as established by medical history and clinical examination before entering into the study.
* Singleton pregnancy (including instances where the singleton pregnancy derives from a vanishing twin syndrome).
* At 24^0/7 to 34^0/7 weeks of gestation at the time of study vaccination (Visit 1), as established by:
* last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S) i.e. at or before 28 weeks of gestation.
* 1st or 2nd trimester U/S only, if LMP is unknown/uncertain
* Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also acceptable.
* No fetal genetic abnormalities (based on genetic testing, if performed).
* No significant congenital malformations, as assessed by fetal anomaly ultrasound scan conducted at or beyond 18 weeks of gestation.
* Willing to provide cord blood.
* Who do not plan to give their child for adoption.
* Who plan to reside in the study area for at least one year after delivery.
* Willing to have the infant followed-up after delivery for a period of 12 months.
Infant participants
* Live-born from the study pregnancy.
* If required per local regulations/guidelines, re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant's mother and/or father and/or LAR, before performing any study specific procedure. OR, if permitted by local regulation, documented verbal consent for infant's participation obtained from the parent(s)/LAR(s) at birth, followed by written consent obtained by (or before) Visit 2-newborn.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
49
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Maternal participants Medical conditions
* History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine
* Hypersensitivity to latex
* Significant complications in the current pregnancy:
* Gestational hypertension unless blood pressure it is controlled and maintained in the normal range (<140mmHg and <90mmHg) through diet and/or antihypertensive medications
* Gestational diabetes not controlled by medication, diet and/or exercise
* Pre-eclampsia
* Eclampsia
* Intrauterine Growth Restriction/Fetal Growth Restriction
* Placenta previa
* Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that can impair the maternal-fetal circulation
* Polyhydramnios
* Oligohydramnios
* Preterm labour or history of preterm labour in the current pregnancy
* Any intervention to prevent preterm delivery or medical treatment for suspected preterm delivery, including administration of systemic corticosteroids for fetal lung maturation
* Cholestasis
* Other pregnancy-related complications (per investigator's judgement)
* Significant structural abnormalities of the uterus or cervix
* History of 2 or more prior stillbirths or neonatal deaths/history of 2 or more preterm births at =34 weeks gestation/3 or more consecutive spontaneous abortions
* Known HIV infection (as per serological tests performed during the current pregnancy)
* Known or suspected HBV or HCV infection
* Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex
* Active infection with tuberculosis
* Known or suspected impairment of the immune system
* Current autoimmune disorder for which the participant has received immune-modifying therapy within 6 months before study vaccination, or plans administration through delivery
* Lymphoproliferative disorder or malignancy within 5 years before study vaccination
* Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions that might pose additional risk to the participant due to participation in the study
* Any conditions that may interfere with participant's ability to comply with study procedures or receipt of prenatal care
* Any condition which would increase the risks of study participation to the unborn infant
Prior/Concomitant therapy
* Prior receipt of an RSV vaccine in the current pregnancy
* Use of any investigational/non-registered product other than the study vaccine/product as described below, or planned use during the period :
* For a drug, vaccine or medical device: from 29 days before the dose of study vaccine
* For immunoglobulins: 3 months before the dose of study vaccine/product.
The exception to this is investigational products administered in the setting of a pandemic which may be allowed following delivery
* Planned administration/administration of any vaccine from 29 days before the dose of study vaccine or planned administration through delivery, except:
* Seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap - alone vaccines, dTpa/Tdap vaccines that also contain other antigens, Hepatitis B vaccines, and COVID-19 vaccines all of which may be administered according to standard of care =15 days before or after study vaccination
* Administration of immunoglobulins (except anti-Rh0D IG, which may be administered at any time), blood products or plasma derivatives within 3 months before study vaccination or planned administration through delivery
* Administration of immune-modifying therapy within 6 months before the study vaccination, or planned administration through delivery. This includes but is not limited to:
* Azathioprine, mycophenolate mofetil, 6-mercaptopurine, cyclosporine, tacrolimus, monoclonal or polyclonal antibodies
* Prednisone =5 mg/day or equivalent for =14 days; Inhaled, intra-articular/intra-bursal and topical steroids are allowed
* Corticosteroids administered for fetal lung maturation
Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product
Other exclusions
* Alcoholism or substance use disorder within the past 24 months based on DSM-5 criteria
* A local condition that precludes injection of the study vaccine/product or precludes assessment of local reactogenicity
* Consanguinity of maternal participant and her partner (second degree cousins or closer)
* Any study personnel or their immediate dependants, family or household members
Infant participants
* Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product
* Any condition which would increase the risks of study participation to the infant
* Child in care.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/11/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/06/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
11194
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - South Brisbane
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Southport
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Clayton
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Geelong
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Montana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nebraska
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Mexico
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
South Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Buenos Aires
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Ciudad AutOnoma de Buenos Aire
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Cordoba
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
San Miguel de TucumAn
Query!
Country [20]
0
0
Argentina
Query!
State/province [20]
0
0
Tucuman
Query!
Country [21]
0
0
Bangladesh
Query!
State/province [21]
0
0
Matlab
Query!
Country [22]
0
0
Bangladesh
Query!
State/province [22]
0
0
Sylhet
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Genk
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Gent
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Kortrijk
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Leuven
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Sint-Niklaas
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Caxias do Sul
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Nova IguaCu
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Porto Alegre
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
RibeirAo PretoSP
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Santa Maria
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
SAo JosE do Rio Preto
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Nova Scotia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Colombia
Query!
State/province [37]
0
0
Barranquilla
Query!
Country [38]
0
0
Colombia
Query!
State/province [38]
0
0
Bogota
Query!
Country [39]
0
0
Colombia
Query!
State/province [39]
0
0
Cali Colombia
Query!
Country [40]
0
0
Colombia
Query!
State/province [40]
0
0
Chia
Query!
Country [41]
0
0
Colombia
Query!
State/province [41]
0
0
Medellin
Query!
Country [42]
0
0
Dominican Republic
Query!
State/province [42]
0
0
Santo Domingo Este
Query!
Country [43]
0
0
Finland
Query!
State/province [43]
0
0
Helsinki
Query!
Country [44]
0
0
Finland
Query!
State/province [44]
0
0
Kokkola
Query!
Country [45]
0
0
Finland
Query!
State/province [45]
0
0
Oulu
Query!
Country [46]
0
0
Finland
Query!
State/province [46]
0
0
Tampere
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Turku
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Bordeaux
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Clermont-Ferrand Cedex 1
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Montpellier cedex
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Paris
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Pierre BEnite
Query!
Country [53]
0
0
Honduras
Query!
State/province [53]
0
0
Comayagua
Query!
Country [54]
0
0
Honduras
Query!
State/province [54]
0
0
San Pedro Sula
Query!
Country [55]
0
0
India
Query!
State/province [55]
0
0
Kolkata
Query!
Country [56]
0
0
India
Query!
State/province [56]
0
0
Mangalore
Query!
Country [57]
0
0
India
Query!
State/province [57]
0
0
Mysore
Query!
Country [58]
0
0
India
Query!
State/province [58]
0
0
Nagpur
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Pune
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Vadu Budruk Pune
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Bari
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Messina
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Milano
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Novara
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Palermo
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Prato
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Verona
Query!
Country [68]
0
0
Korea, Republic of
Query!
State/province [68]
0
0
Daegu
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Seoul
Query!
Country [70]
0
0
Mexico
Query!
State/province [70]
0
0
Chihuahua
Query!
Country [71]
0
0
Mexico
Query!
State/province [71]
0
0
Monterrey
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Morelia
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Oaxaca
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
San Juan Del RIo
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
San Luis PotosI
Query!
Country [76]
0
0
New Zealand
Query!
State/province [76]
0
0
Grafton Auckland
Query!
Country [77]
0
0
New Zealand
Query!
State/province [77]
0
0
Papatoetoe Auckland
Query!
Country [78]
0
0
New Zealand
Query!
State/province [78]
0
0
Wellington
Query!
Country [79]
0
0
Panama
Query!
State/province [79]
0
0
Ciudad de Panama
Query!
Country [80]
0
0
Panama
Query!
State/province [80]
0
0
Panama City
Query!
Country [81]
0
0
Panama
Query!
State/province [81]
0
0
Panama
Query!
Country [82]
0
0
Philippines
Query!
State/province [82]
0
0
Cavite
Query!
Country [83]
0
0
Philippines
Query!
State/province [83]
0
0
Manila
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Johannesburg
Query!
Country [85]
0
0
South Africa
Query!
State/province [85]
0
0
Pretoria
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Soshanguve
Query!
Country [87]
0
0
South Africa
Query!
State/province [87]
0
0
Soweto
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Aravaca
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Barcelona
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Bilbao
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Boadilla Del Monte Madrid
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Burgos
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Getafe
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Madrid
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Malaga
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Marbella
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Sevilla
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
TorrejOn Ardoz Madrid
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Valencia
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Valladolid
Query!
Country [101]
0
0
Taiwan
Query!
State/province [101]
0
0
Changhua
Query!
Country [102]
0
0
Taiwan
Query!
State/province [102]
0
0
Kaohsiung
Query!
Country [103]
0
0
Taiwan
Query!
State/province [103]
0
0
Taichung
Query!
Country [104]
0
0
Taiwan
Query!
State/province [104]
0
0
Taipei
Query!
Country [105]
0
0
Taiwan
Query!
State/province [105]
0
0
Taoyuan
Query!
Country [106]
0
0
Thailand
Query!
State/province [106]
0
0
Bangkok
Query!
Country [107]
0
0
Thailand
Query!
State/province [107]
0
0
ChiangMai
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
Edinburgh
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study was to evaluate the ability of a single dose of the investigational RSV Maternal vaccine, administered intramuscularly (IM) to pregnant women aged 18-49 years, in good general maternal health, in preventing medically assessed RSV associated Lower Respiratory Tract Illnesses (LRTIs) in infants born to vaccinated mothers. The study also evaluated the safety of the investigational RSV Maternal vaccine both in vaccinated mothers and in their corresponding infant. Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study. Ongoing study participants at that time continued to be monitored as part of the study.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04605159
Query!
Trial related presentations / publications
Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann JU, Swamy GK, Webster P, Dormitzer PR. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. N Engl J Med. 2024 Mar 14;390(11):1009-1021. doi: 10.1056/NEJMoa2305478. Ginsburg AS, Srikantiah P. Respiratory syncytial virus: promising progress against a leading cause of pneumonia. Lancet Glob Health. 2021 Dec;9(12):e1644-e1645. doi: 10.1016/S2214-109X(21)00455-1. Epub 2021 Nov 11. No abstract available.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Query!
Available to whom?
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/59/NCT04605159/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/59/NCT04605159/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04605159
Download to PDF